Advances in Systemic Immunotherapies of Melanoma and Other Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (20 September 2023) | Viewed by 2458

Special Issue Editor


E-Mail Website
Guest Editor
Department of Surgery, University of Adelaide, Adelaide, Australia
Interests: melanoma; breast cancer; surgery; surgical oncology; vaccine treatment of cancer; skin cancer; immunology; immune system and cancer; cancer treatment; surgical complications; clinical skills; epidemiology

Special Issue Information

Dear Colleagues,

Our understanding of cancer genesis and control has taken another leap forward with recent advances in immunotherapies and our knowledge of the role of the immune system in cancer modulation.

This has provided some novel conceptual models explaining the complexity of the cancer microenvironment and its interaction with the immune system in a bimodal manner, meaning it is able to modulate either activation or tolerance, the balance of which impacts the clinical outcome.

Our comprehension of this dynamic interaction between cancer cells, stroma and the immunological system is only just beginning, and the mechanisms involved are gradually being elucidated. Indeed, with the recent development of COVID-19 vaccine technologies, a new era of potential therapeutic vaccinations for established cancers is developing considerable momentum. The realisation that radiation, cytotoxic chemotherapy and even surgical treatments can induce vaccination effects and immunological responses is proving extremely exciting and scientifically informative. Emerging observations of “local” versus “systemic” cancer control are rapidly leading to the revelation that there is much overlap and synergy, inviting the development of new concepts of “systemic” cancer therapy.

In this Special Issue, we aim to bring together some fascinating concepts and approaches to clinical cancer treatments and the underlying mechanisms for modulating the immune system to add to the rapidly accumulating substantial evidence based on cancer immunotherapies.

Dr. Brendon J. Coventry
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • melanoma
  • immunotherapy
  • systemic therapies
  • vaccination

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

20 pages, 2299 KiB  
Systematic Review
The Effectiveness of Cancer Immune Checkpoint Inhibitor Retreatment and Rechallenge—A Systematic Review
by Adrian Perdyan, Bartosz Kamil Sobocki, Amar Balihodzic, Anna Dąbrowska, Justyna Kacperczyk and Jacek Rutkowski
Cancers 2023, 15(13), 3490; https://doi.org/10.3390/cancers15133490 - 4 Jul 2023
Cited by 5 | Viewed by 2178
Abstract
Despite a great success of immunotherapy in cancer treatment, a great number of patients will become resistant. This review summarizes recent reports on immune checkpoint inhibitor retreatment or rechallenge in order to overcome primary resistance. The systematic review was performed according to PRISMA [...] Read more.
Despite a great success of immunotherapy in cancer treatment, a great number of patients will become resistant. This review summarizes recent reports on immune checkpoint inhibitor retreatment or rechallenge in order to overcome primary resistance. The systematic review was performed according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. The search was performed using PubMed, Web of Science and Scopus. In total, 31 articles were included with a total of 812 patients. There were 16 retreatment studies and 13 rechallenge studies. We identified 15 studies in which at least one parameter (overall response rate or disease control rate) improved or was stable at secondary treatment. Interval treatment, primary response to and the cause of cessation for the first immune checkpoint inhibitors seem to be promising predictors of secondary response. However, high heterogeneity of investigated cohorts and lack of reporting guidelines are limiting factors for current in-depth analysis. Full article
(This article belongs to the Special Issue Advances in Systemic Immunotherapies of Melanoma and Other Cancers)
Show Figures

Figure 1

Back to TopTop